BE THE DIFFERENCE IN PSORIASIS RESEARCH: BE UNIQUE



Stock photo. Posed by mode

Study Information Brochure





The **BE UNIQUE Study** may be an opportunity for you to learn more about your psoriasis. You may also be able to contribute to understanding of the link between a person's unique biological make-up and their long-term response to an established psoriasis treatment.

The psoriasis treatment being studied in BE UNIQUE is called **bimekizumab**. Doctors in multiple countries across North America and Europe are already able to prescribe bimekizumab as treatment for people who have moderate to severe plaque psoriasis.

You and all other study participants with psoriasis will receive bimekizumab. To allow the researchers to understand the link between your unique biological make-up and your response to bimekizumab, the study team will compare changes in your skin over the course of the study.

The BE UNIQUE Study community will include approximately 80 adults who meet the following criteria:

- At least 18 years of age (at the time of joining)
- Have **plaque psoriasis** diagnosed at least 6 months ago
- With or without active psoriatic arthritis

There will be further checks to see if you are eligible to join. A member of the study team will discuss these with you.

Your health and response to bimekizumab will be monitored in many ways, including the following:



Taking small samples of your blood



Rating your psoriasis and how it affects you (body surface area affected, itching, and quality of life)



Photographing your skin



Skin biopsies – removing very small pieces of your skin after it is suitably numbed



Checking your joint health if you also have psoriatic arthritis



Measuring your blood pressure, pulse rate, and body temperature

Taking part in the BE UNIQUE Study includes the following:



Contact the study team to find out more about the study and arrange a Screening Visit.



At a Screening Visit, the study Doctor will check if the study is right for you, and if you are right for the study.



If you are eligible and decide you do want to participate, you will begin your BE UNIQUE Study journey.



- All study participants with psoriasis receive bimekizumab
- Bimekizumab given by injections just under the skin
- All study injections given at study center visits



- Up to **105 weeks**
- 18 visits for health checks
- Between 12 and 14 doses of bimekizumab
- Time between injections ranging from 4 to a maximum of 12 weeks
- Comprehensive monitoring of your psoriasis throughout



After all study participants have finished and the information has been processed, a summary of the study findings will be made available in easy to understand language.



- Support from a team of healthcare professionals dedicated to ensuring your safety and well-being throughout the study
- No charge for the study treatment or study-related care



Participation is voluntary and completely your choice. You do not have to join. If you choose to take part, you can leave any time you want to with no penalty to you or your standard healthcare.

Diversity and inclusion are key to conducting the best clinical research possible – we strive to recruit a true cross-section of society to ensure that every person feels represented in our research efforts.





What's next?

- Find your nearest participating study center on the website.
- Get in touch using the provided contact details to discuss the study further and arrange a Screening visit.

Contacting us does not mean that you must join the study or that you will be able to participate.

We will happily provide the information you need to make an informed decision.

Thank you for your interest in BE UNIQUE.



